- Home
- ELVN
as of 01-13-2026 3:40pm EST
$25.42
+$0.39
+1.57%
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $41.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $29.98 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ELVN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.83%
70.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
Patel Anish
Sell
CHIEF OPERATING OFFICER
ELVN Jan 9, 2026
Avg Cost/Share
$28.24
Shares
48,300
Total Value
$1,351,762.20
Owned After
215,011
Lyssikatos Joseph P
Sell
CHIEF SCIENTIFIC OFFICER
ELVN Jan 9, 2026
Avg Cost/Share
$27.02
Shares
91,198
Total Value
$2,482,578.16
Owned After
765,188
Heyman Richard A.
Sell
Director
ELVN Jan 9, 2026
Avg Cost/Share
$25.00
Shares
4,285
Total Value
$107,125.43
Owned After
25,107
SEC Form 4
Lyssikatos Joseph P
Sell
CHIEF SCIENTIFIC OFFICER
ELVN Jan 8, 2026
Avg Cost/Share
$22.53
Shares
41,302
Total Value
$993,435.79
Owned After
765,188
Heyman Richard A.
Sell
Director
ELVN Jan 8, 2026
Avg Cost/Share
$25.02
Shares
9,635
Total Value
$241,155.53
Owned After
25,107
Lyssikatos Joseph P
Sell
CHIEF SCIENTIFIC OFFICER
ELVN Dec 19, 2025
Avg Cost/Share
$16.84
Shares
5,000
Total Value
$84,206.00
Owned After
765,188
SEC Form 4
Patel Anish
Sell
CHIEF OPERATING OFFICER
ELVN Dec 8, 2025
Avg Cost/Share
$21.27
Shares
6,663
Total Value
$140,072.86
Owned After
215,011
Kintz Samuel
Sell
PRESIDENT AND CEO
ELVN Nov 17, 2025
Avg Cost/Share
$21.82
Shares
12,500
Total Value
$272,738.75
Owned After
890,392
SEC Form 4
Patel Anish
Sell
CHIEF OPERATING OFFICER
ELVN Nov 7, 2025
Avg Cost/Share
$17.64
Shares
6,667
Total Value
$116,034.16
Owned After
215,011
Lyssikatos Joseph P
Sell
CHIEF SCIENTIFIC OFFICER
ELVN Oct 20, 2025
Avg Cost/Share
$22.08
Shares
12,500
Total Value
$276,025.00
Owned After
765,188
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jan 9, 2026 | Sell | $28.24 | 48,300 | $1,351,762.20 | 215,011 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jan 9, 2026 | Sell | $27.02 | 91,198 | $2,482,578.16 | 765,188 | |
| Heyman Richard A. | ELVN | Director | Jan 9, 2026 | Sell | $25.00 | 4,285 | $107,125.43 | 25,107 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jan 8, 2026 | Sell | $22.53 | 41,302 | $993,435.79 | 765,188 | |
| Heyman Richard A. | ELVN | Director | Jan 8, 2026 | Sell | $25.02 | 9,635 | $241,155.53 | 25,107 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Dec 19, 2025 | Sell | $16.84 | 5,000 | $84,206.00 | 765,188 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Dec 8, 2025 | Sell | $21.27 | 6,663 | $140,072.86 | 215,011 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Nov 17, 2025 | Sell | $21.82 | 12,500 | $272,738.75 | 890,392 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Nov 7, 2025 | Sell | $17.64 | 6,667 | $116,034.16 | 215,011 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Oct 20, 2025 | Sell | $22.08 | 12,500 | $276,025.00 | 765,188 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
MT Newswires
Enliven Therapeutics Leukemia Drug Achieves 69% Response Rate in Phase 1b Trial
➖
AI Sentiment
Neutral
5/10
PR Newswire
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
📈
AI Sentiment
Highly Positive
9/10
Compare ELVN vs Leading Stocks
See how ELVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.